Small Cell Lung Cancer

By G. Kalemkerian, Wallace Akerley, Paul N. Bogner, Hossein Borghaei, Laura Q. Chow, Robert J Downey, L. Gandhi, A. Ganti, Ramaswamy Govindan, J. Grecula and 16 more. Recent Results in Cancer Research, 2010

2,387 citations recorded by the source corpus.

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d995eb380a36e06110d2db56f0e65b6476dd6062

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Rajkumar
2. C. Zappa
3. Aadel A Chaudhuri
4. Shaker A. Mousa
5. Aaron M. Newman

In Oncology

1. S. Rajkumar
2. C. Zappa
3. Shaker A. Mousa

Citations in the corpus

• Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “surveillance involves serial radiographic imaging (1,2).”
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. (2003, neutral): “However, the vast majority of cases of SCLC recur and then rapidly progress, with a median survival time of 7–10 months (2).”
• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009, positive): “Similar recommendations have been put forth by Mayo Clinic physicians to guide treatment of other cancers.(9-20) When specific evidence is lacking, our group of 21 Mayo Clinic myeloma experts reached a consensus based on current practice patterns.”
• A small cell lung cancer genome reports complex tobacco exposure signatures (2009, neutral): “(7) Institute of Cancer Research, Sutton, Surrey, UK”
• Non-small cell lung cancer: current treatment and future advances. (2016, background): “There are two main subtypes of lung cancer, smallcell lung carcinoma and non-small-cell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively (4).”